IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-32263-7.html
   My bibliography  Save this article

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

Author

Listed:
  • Alessandra Vergori

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Alessandro Cozzi Lepri

    (Institute for Global Health, UCL)

  • Stefania Cicalini

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Giulia Matusali

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Veronica Bordoni

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Simone Lanini

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Silvia Meschi

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Roberta Iannazzo

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Valentina Mazzotta

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Francesca Colavita

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Ilaria Mastrorosa

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Eleonora Cimini

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Davide Mariotti

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Lydia De Pascale

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Alessandra Marani

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Paola Gallì

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • AnnaRosa Garbuglia

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Concetta Castilletti

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Vincenzo Puro

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Chiara Agrati

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Enrico Girardi

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Francesco Vaia

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

  • Andrea Antinori

    (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS)

Abstract

In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count 2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.

Suggested Citation

  • Alessandra Vergori & Alessandro Cozzi Lepri & Stefania Cicalini & Giulia Matusali & Veronica Bordoni & Simone Lanini & Silvia Meschi & Roberta Iannazzo & Valentina Mazzotta & Francesca Colavita & Ilar, 2022. "Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32263-7
    DOI: 10.1038/s41467-022-32263-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-32263-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-32263-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Farina Karim & Catherine Riou & Mallory Bernstein & Zesuliwe Jule & Gila Lustig & Strauss Graan & Roanne S. Keeton & Janine-Lee Upton & Yashica Ganga & Khadija Khan & Kajal Reedoy & Matilda Mazibuko &, 2024. "Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation," Nature Communications, Nature, vol. 15(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32263-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.